TTK Healthcare Adjusts Valuation Grade Amid Competitive Industry Landscape

TTK Healthcare, a small-cap player in the Pharmaceuticals & Drugs sector, has recently undergone a valuation adjustment. The company's current price stands at 1,230.00, reflecting a slight increase from the previous close of 1,196.60. Over the past week, TTK Healthcare has shown a stock return of 11.59%, outperforming the Sensex, which returned 5.14% in the same period.
Key financial metrics reveal a PE ratio of 25.38 and a price-to-book value of 1.67. The company's EV to EBIT is recorded at 37.90, while the EV to EBITDA stands at 27.71. TTK Healthcare's return on capital employed (ROCE) is 8.02%, and its return on equity (ROE) is 6.59%. The dividend yield is noted at 0.81%.

In comparison to its peers, TTK Healthcare's valuation metrics indicate a competitive position within the industry. For instance, Orchid Pharma and RPG LifeScience are positioned at higher valuation levels, while companies like Sequent Scientific and Dishman Carbogen are similarly rated. This context highlights TTK Healthcare's relative standing in a diverse market landscape.